Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Monitoring ketamine treatment response in a depressed patient via peripheral mammalian target of rapamycin activation.

Literature DB >> 21724677

Monitoring ketamine treatment response in a depressed patient via peripheral mammalian target of rapamycin activation.

Magdalena C Denk, Christiane Rewerts, Florian Holsboer, Angelika Erhardt-Lehmann, Christoph W Turck.

Abstract

Entities: Chemical Disease Species

Mesh：

Substances：

Year: 2011 PMID： 21724677 DOI： 10.1176/appi.ajp.2011.11010128

Source DB: PubMed Journal: Am J Psychiatry ISSN： 0002-953X Impact factor: 18.112

Keyword Cloud
Cited

× No keyword cloud information.

24 in total

Review 1. Ketamine for depression: where do we go from here?

Authors: Marije Aan Het Rot; Carlos A Zarate; Dennis S Charney; Sanjay J Mathew
Journal: Biol Psychiatry Date: 2012-06-16 Impact factor: 13.382

Review 2. New targets for rapid antidepressant action.

Authors: Rodrigo Machado-Vieira; Ioline D Henter; Carlos A Zarate
Journal: Prog Neurobiol Date: 2015-12-23 Impact factor: 11.685

Review 3. Glutamate receptor antagonists as fast-acting therapeutic alternatives for the treatment of depression: ketamine and other compounds.

Authors: Mark J Niciu; Ioline D Henter; David A Luckenbaugh; Carlos A Zarate; Dennis S Charney
Journal: Annu Rev Pharmacol Toxicol Date: 2014 Impact factor: 13.820

Review 4. Developing biomarkers in mood disorders research through the use of rapid-acting antidepressants.

Authors: Mark J Niciu; Daniel C Mathews; Allison C Nugent; Dawn F Ionescu; Maura L Furey; Erica M Richards; Rodrigo Machado-Vieira; Carlos A Zarate
Journal: Depress Anxiety Date: 2013-12-18 Impact factor: 6.505

Review 5. Esketamine: a glimmer of hope in treatment-resistant depression.

Authors: Upinder Kaur; Bhairav Kumar Pathak; Amit Singh; Sankha Shubhra Chakrabarti
Journal: Eur Arch Psychiatry Clin Neurosci Date: 2019-11-19 Impact factor: 5.270

6. Glutamatergic system and mTOR-signaling pathway participate in the antidepressant-like effect of inosine in the tail suspension test.

Authors: Filipe Marques Gonçalves; Vivian Binder Neis; Débora Kurrle Rieger; Tanara V Peres; Mark William Lopes; Isabella A Heinrich; Ana Paula Costa; Ana Lúcia S Rodrigues; Manuella P Kaster; Rodrigo Bainy Leal
Journal: J Neural Transm (Vienna) Date: 2017-07-10 Impact factor: 3.575

Monitoring ketamine treatment response in a depressed patient via peripheral mammalian target of rapamycin activation.

Review 1. Ketamine for depression: where do we go from here?

Review 2. New targets for rapid antidepressant action.

Review 3. Glutamate receptor antagonists as fast-acting therapeutic alternatives for the treatment of depression: ketamine and other compounds.

Review 4. Developing biomarkers in mood disorders research through the use of rapid-acting antidepressants.

Review 5. Esketamine: a glimmer of hope in treatment-resistant depression.

6. Glutamatergic system and mTOR-signaling pathway participate in the antidepressant-like effect of inosine in the tail suspension test.

7. Everolimus induced mood changes in breast cancer patients: a case-control study.

Review 8. Glutamate and its receptors in the pathophysiology and treatment of major depressive disorder.

9. Plasma brain derived neurotrophic factor (BDNF) and response to ketamine in treatment-resistant depression.

10. Antidepressant effects of AMPA and ketamine combination: role of hippocampal BDNF, synapsin, and mTOR.